Pseudomonas predators: Understanding and exploiting phage-host interactions

Nature Reviews Microbiology

Volumn 15, Issue 9, 2017, Pages 517-530

  De Smet, Jeroen ^a   Hendrix, Hanne ^a   Blasdel, Bob G ^a   Danis Wlodarczyk, Katarzyna ^a   Lavigne, Rob ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL GENOME; BACTERIAL VIRULENCE; BIOTECHNOLOGY; ECOLOGICAL NICHE; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; NONHUMAN; PHAGE THERAPY; PRIORITY JOURNAL; PROPHAGE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGE; PSEUDOMONAS SYRINGAE; REVIEW; GENETICS; GROWTH, DEVELOPMENT AND AGING; PSEUDOMONAS; VIROLOGY;

HOST-PATHOGEN INTERACTIONS; HUMANS; PSEUDOMONAS; PSEUDOMONAS PHAGES;

EID: 85027990190     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro.2017.61     Document Type: Review

References (173)

1. Silby, M. W., Winstanley, C., Godfrey, S. A. C., Levy, S. B. & Jackson, R. W. Pseudomonas genomes: diverse and adaptable. FEMS Microbiol. Rev. 35, 652-680 (2011).
2. Stover, C. K. et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959-964 (2000).
3. Kung, V. L., Ozer, E. A. & Hauser, A. R. The accessory genome of Pseudomonas aeruginosa. Microbiol. Mol. Biol. Rev. 74, 621-641 (2010).
4. Freschi, L. et al. Clinical utilization of genomics data produced by the International Pseudomonas aeruginosa Consortium. Front. Microbiol. 6, 1036 (2015).
5. Breidenstein, E. B. M., de la Fuente-Núñez, C. & Hancock, R. E. W. Pseudomonas aeruginosa: All roads lead to resistance. Trends Microbiol. 19, 419-426 (2011).
6. Ceyssens, P.J. & Lavigne, R. Bacteriophages of Pseudomonas. Future Microbiol. 5, 1041-1055 (2010).
7. James, C. E. et al. Lytic activity by temperate phages of Pseudomonas aeruginosa in long-term cystic fibrosis chronic lung infections. ISME J. 9, 1391-1398 (2015).
8. Hatfull, G. F. & Hendrix, R. W. Bacteriophages and their genomes. Curr. Opin. Virol. 1, 298-303 (2011).
9. Cazares, A. et al. Core and accessory genome architecture in a group of Pseudomonas aeruginosa Mulike phages. BMC Genomics 15, 1146 (2014).
10. Rohwer, F. & Youle, M. Consider something viral in your research. Nat. Rev. Microbiol. 9, 308-309 (2011).
11. Yin, Y. & Fischer, D. Identification and investigation of ORFans in the viral world. BMC Genomics 9, 24 (2008).
12. Hatfull, G. F. Dark matter of the biosphere: The amazing world of bacteriophage diversity. J. Virol. 89, 8107-8110 (2015).
13. Sepúlveda-Robles, O., Kameyama, L. & Guarneros, G. High diversity and novel species of Pseudomonas aeruginosa bacteriophages. Appl. Environ. Microbiol. 78, 4510-4515 (2012).
14. Ceyssens, P.J. et al. Survey of Pseudomonas aeruginosa and its phages: de novo peptide sequencing as a novel tool to assess the diversity of worldwide collected viruses. Environ. Microbiol. 11, 1303-1313 (2009).
15. Kwan, T., Liu, J., Dubow, M., Gros, P. & Pelletier, J. Comparative genomic analysis of 18 Pseudomonas aeruginosa bacteriophages. J. Bacteriol. 188, 1184-1187 (2006).
16. Angly, F. E. et al. The marine viromes of four oceanic regions. PLoS Biol. 4, e368 (2006).
17. Tümmler, B., Wiehlmann, L., Klockgether, J. & Cramer, N. Advances in understanding Pseudomonas. F1000Prime Rep. 6, 9 (2014).
18. Brockhurst, M. A., Fenton, A., Roulston, B. & Rainey, P. B. The impact of phages on interspecific competition in experimental populations of bacteria. BMC Ecol. 6, 19 (2006).
19. Buckling, A. & Rainey, P. B. The role of parasites in sympatric and allopatric host diversification. Nature 420, 496-499 (2002).
20. Feiner, R. et al. A new perspective on lysogeny: prophages as active regulatory switches of bacteria. Nat. Rev. Microbiol. 13, 641-650 (2015).
21. Cenens, W. et al. Expression of a novel P22 ORFan gene reveals the phage carrier state in Salmonella Typhimurium. PLoS Genet. 9, e1003269 (2013).
22. Cenens, W., Makumi, A., Govers, S. K., Lavigne, R. & Aertsen, A. Viral transmission dynamics at single-cell resolution reveal transiently immune subpopulations caused by a carrier state association. PLoS Genet. 11, e1005770 (2015).
23. Samson, J. E., Magadán, A. H., Sabri, M. & Moineau, S. Revenge of the phages: defeating bacterial defences. Nat. Rev. Microbiol. 11, 675-687 (2013).
24. Paterson, S. et al. Antagonistic coevolution accelerates molecular evolution. Nature 464, 275-278 (2010).
25. Scanlan, P. D., Hall, A. R., Lopez-Pascua, L. D. C. & Buckling, A. Genetic basis of infectivity evolution in a bacteriophage. Mol. Ecol. 20, 981-989 (2011).
26. Le, S. et al. Mapping the tail fiber as the receptor binding protein responsible for differential host specificity of Pseudomonas aeruginosa bacteriophages PaP1 and JG004. PLoS ONE 8, e68562 (2013).
27. Cornelissen, A. et al. The T7related Pseudomonas putida phage ?15 displays virion-associated biofilm degradation properties. PLoS ONE 6, e18597 (2011).
28. Cornelissen, A. et al. Identification of EPS-degrading activity within the tail spikes of the novel Pseudomonas putida phage AF. Virology 434, 251-256 (2012).
29. Glonti, T., Chanishvili, N. & Taylor, P. W. Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa. J. Appl. Microbiol. 108, 695-702 (2010).
30. Chung, I.Y., Jang, H.J., Bae, H.W. & Cho, Y.H. A phage protein that inhibits the bacterial ATPase required for type IV pilus assembly. Proc. Natl Acad. Sci. USA 111, 11503-11508 (2014).
31. Bondy-Denomy, J. et al. Prophages mediate defense against phage infection through diverse mechanisms. ISME J. 10, 2854-2866 (2016).
32. Weigele, P. & Raleigh, E. A. Biosynthesis and function of modified bases in bacteria and their viruses. Chem. Rev. 116, 12655-12687 (2016).
33. Ceyssens, P.J. et al. The genome and structural proteome of YuA, a new Pseudomonas aeruginosa phage resembling M6. J. Bacteriol. 190, 1429-1435 (2008).
34. Barrangou, R. et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709-1712 (2007).
35. Garneau, J. E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67-71 (2010).
36. van Belkum, A. et al. Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant Pseudomonas aeruginosa. mBio 6, e0179615 (2015).
37. Pawluk, A. et al. Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species. Nat. Microbiol. 1, 16085 (2016).
38. Bondy-Denomy, J., Pawluk, A., Maxwell, K. L. & Davidson, A. R. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature 493, 429-432 (2013).
39. Bondy-Denomy, J. et al. Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR proteins. Nature 526, 136-139 (2015).
40. Pawluk, A., Bondy-Denomy, J., Cheung, V. H. W., Maxwell, K. L. & Davidson, A. R. A. New group of phage anti-CRISPR genes inhibits the type IE CRISPR-Cas system of Pseudomonas aeruginosa. mBio 5, e0089614 (2014).
41. Cady, K. C., Bondy-Denomy, J., Heussler, G. E., Davidson, A. R. & O'Toole, G. A. The CRISPR/Cas adaptive immune system of Pseudomonas aeruginosa mediates resistance to naturally occurring and engineered phages. J. Bacteriol. 194, 5728-5738 (2012).
42. Ali, S. S., Xia, B., Liu, J. & Navarre, W. W. Silencing of foreign DNA in bacteria. Curr. Opin. Microbiol. 15, 175-181 (2012).
43. Castang, S., McManus, H. R., Turner, K. H. & Dove, S. L. HNS family members function coordinately in an opportunistic pathogen. Proc. Natl Acad. Sci. USA 105, 18947-18952 (2008).
44. Castang, S. & Dove, S. L. Basis for the essentiality of HNS family members in Pseudomonas aeruginosa. J. Bacteriol. 194, 5101-5109 (2012).
45. Wagemans, J. et al. Antibacterial phage ORFans of Pseudomonas aeruginosa phage LUZ24 reveal a novel MvaT inhibiting protein. Front. Microbiol. 6, 1242 (2015).
46. Roucourt, B. & Lavigne, R. The role of interactions between phage and bacterial proteins within the infected cell: A diverse and puzzling interactome. Environ. Microbiol. 11, 2789-2805 (2009).
47. Wagemans, J. et al. Functional elucidation of antibacterial phage ORFans targeting Pseudomonas aeruginosa. Cell. Microbiol. 16, 1822-1835 (2014).
48. Van den Bossche, A. et al. Systematic identification of hypothetical bacteriophage proteins targeting key protein complexes of Pseudomonas aeruginosa. J. Proteome Res. 13, 4446-4456 (2014).
49. Ceyssens, P.J. et al. Development of giant bacteriophage ?KZ is independent of the host transcription apparatus. J. Virol. 88, 10501-10510 (2014).
50. Yakunina, M. et al. A non-canonical multisubunit RNA polymerase encoded by a giant bacteriophage. Nucleic Acids Res. 43, 10411-10420 (2015).
51. Lavigne, R. et al. A multifaceted study of Pseudomonas aeruginosa shutdown by virulent podovirus LUZ19. mBio 4, e0006113 (2013).
52. Klimuk, E. et al. Host RNA polymerase inhibitors encoded by ?KMV-like phages of Pseudomonas. Virology 436, 67-74 (2013).
53. Qimron, U., Kulczyk, A. W., Hamdan, S. M., Tabor, S. & Richardson, C. C. Inadequate inhibition of host RNA polymerase restricts T7 bacteriophage growth on hosts overexpressing udk. Mol. Microbiol. 67, 448-457 (2007).
54. Sheppard, C. et al. A non-bacterial transcription factor inhibits bacterial transcription by a multipronged mechanism. RNA Biol. 10, 495-501 (2013).
55. Ravantti, J. J., Ruokoranta, T. M., Alapuranen, A. M. & Bamford, D. H. Global transcriptional responses of Pseudomonas aeruginosa to phage PRR1 infection. J. Virol. 82, 2324-2329 (2008).
56. Van den Bossche, A. et al. Structural elucidation of a novel mechanism for the bacteriophage-based inhibition of the RNA degradosome. eLife 5, e16413 (2016).
57. Dendooven, T. et al. Viral interference of the bacterial RNA metabolism machinery. RNA Biol. 14, 6-10 (2016).
58. Chevallereau, A. et al. Next-generation '-omics' approaches reveal a massive alteration of host RNA metabolism during bacteriophage infection of Pseudomonas aeruginosa. PLoS Genet. 12, e1006134 (2016).
59. Breitbart, M., Thompson, L. R., Suttle, C. A. & Sullivan, M. B. Exploring the vast diversity of marine viruses. Oceanography 2, 135-139 (2007).
60. Martiny, A. C., Huang, Y. & Li, W. Occurrence of phosphate acquisition genes in Prochlorococcus cells from different ocean regions. Environ. Microbiol. 11, 1340-1347 (2009).
61. Sullivan, M. B. et al. Genomic analysis of oceanic cyanobacterial myoviruses compared with T4like myoviruses from diverse hosts and environments. Environ. Microbiol. 12, 3035-3056 (2010).
62. Lindell, D., Jaffe, J. D., Johnson, Z. I., Church, G. M. & Chisholm, S. W. Photosynthesis genes in marine viruses yield proteins during host infection. Nature 438, 86-89 (2005).
63. Frank, J. A. et al. Structure and function of a cyanophage-encoded peptide deformylase. ISME J. 7, 1150-1160 (2013).
64. Thompson, L. R. et al. Phage auxiliary metabolic genes and the redirection of cyanobacterial host carbon metabolism. Proc. Natl Acad. Sci. USA 108, E757-E764 (2011).
65. Miller, E. S. et al. Bacteriophage T4 genome. Microbiol. Mol. Biol. Rev. 67, 86-156 (2003).
66. Sharon, I. et al. Comparative metagenomics of microbial traits within oceanic viral communities. ISME J. 5, 1178-1190 (2011).
67. Brussaard, C. P. D. et al. Global-scale processes with a nanoscale drive: The role of marine viruses. ISME J. 2, 575-578 (2008).
68. Sonkar, K., Purusottam, R. N. & Sinha, N. Metabonomic study of host-phage interaction by nuclear magnetic resonance-and statistical total correlation spectroscopy-based analysis. Anal. Chem. 84, 4063-4070 (2012).
69. De Smet, J. et al. High coverage metabolomics analysis reveals phage-specific alterations to Pseudomonas aeruginosa physiology during infection. ISME J. 10, 1823-1835 (2016).
70. Liu, J. et al. Antimicrobial drug discovery through bacteriophage genomics. Nat. Biotechnol. 22, 185-191 (2004).
71. Yano, S. T. & Rothman-Denes, L. B. A phage-encoded inhibitor of Escherichia coli DNA replication targets the DNA polymerase clamp loader. Mol. Microbiol. 79, 1325-1338 (2011).
72. Conter, A., Bouché, J. P. & Dassain, M. Identification of a new inhibitor of essential division gene ftsZ as the kil gene of defective prophage Rac. J. Bacteriol. 178, 5100-5104 (1996).
73. Kraemer, J. A. et al. A phage tubulin assembles dynamic filaments by an atypical mechanism to center viral DNA within the host cell. Cell 149, 1488-1499 (2012).
74. Aylett, C. H. S., Izoré, T., Amos, L. A. & Löwe, J. Structure of the tubulin/FtsZlike protein TubZ from Pseudomonas bacteriophage ?KZ. J. Mol. Biol. 425, 2164-2173 (2013).
75. Erb, M. L. et al. A bacteriophage tubulin harnesses dynamic instability to center DNA in infected cells. eLife 3, e03197 (2014).
76. Koskella, B. & Brockhurst, M. A. Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol. Rev. 38, 916-931 (2014).
77. Scanlan, P. D. et al. Coevolution with bacteriophages drives genome-wide host evolution and constrains the acquisition of abiotic-beneficial mutations. Mol. Biol. Evol. 32, 1425-1435 (2015).
78. Bohannan, B. J. M. & Lenski, R. E. Linking genetic change to community evolution: insights from studies of bacteria and bacteriophage. Ecol. Lett. 3, 362-377 (2000).
79. Gómez, P. & Buckling, A. Bacteria-phage antagonistic coevolution in soil. Science 332, 106-109 (2011).
80. Hall, A. R., Scanlan, P. D., Morgan, A. D. & Buckling, A. Host-parasite coevolutionary arms races give way to fluctuating selection. Ecol. Lett. 14, 635-642 (2011).
81. Gorter, F. A., Scanlan, P. D. & Buckling, A. Adaptation to abiotic conditions drives local adaptation in bacteria and viruses coevolving in heterogeneous environments. Biol. Lett. 12, 20150879 (2016).
82. Westra, E. R. et al. Parasite exposure drives selective evolution of constitutive versus inducible defense. Curr. Biol. 25, 1043-1049 (2015).
83. Chabas, H., van Houte, S., Høyland-Kroghsbo, N. M., Buckling, A. & Westra, E. R. Immigration of susceptible hosts triggers the evolution of alternative parasite defence strategies. Proc. R. Soc. B Biol. Sci. 283, 20160721 (2016).
84. Martínez-García, E., Jatsenko, T., Kivisaar, M. & de Lorenzo, V. Freeing Pseudomonas putida KT2440 of its proviral load strengthens endurance to environmental stresses. Environ. Microbiol. 17, 76-90 (2015).
85. Wang, X. & Wood, T. K. Cryptic prophages as targets for drug development. Drug Resist. Updat. 27, 30-38 (2016).
86. Fortier, L.C. & Sekulovic, O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4, 354-365 (2013).
87. Davies, E. V. et al. Temperate phages both mediate and drive adaptive evolution in pathogen biofilms. Proc. Natl Acad. Sci. USA 113, 8266-8271 (2016).
88. Latino, L., Midoux, C., Hauck, Y., Vergnaud, G. & Pourcel, C. Pseudolysogeny and sequential mutations build multiresistance to virulent bacteriophages in Pseudomonas aeruginosa. Microbiology 162, 748-763 (2016).
89. Budzik, J. M., Rosche, W. A., Rietsch, A. & O'Toole, G. A. Isolation and characterization of a generalized transducing phage for Pseudomonas aeruginosa strains PAO1 and PA14. J. Bacteriol. 186, 3270-3273 (2004).
90. Monson, R., Foulds, I., Foweraker, J., Welch, M. & Salmond, G. P. C. The Pseudomonas aeruginosa generalized transducing phage PA3 is a new member of the KZlike group of 'jumbo' phages, and infects model laboratory strains and clinical isolates from cystic fibrosis patients. Microbiology 157, 859-867 (2011).
91. Taylor, T. B. & Buckling, A. Bacterial motility confers fitness advantage in the presence of phages. J. Evol. Biol. 26, 2154-2160 (2013).
92. Scanlan, P. D. & Buckling, A. Coevolution with lytic phage selects for the mucoid phenotype of Pseudomonas fluorescens SBW25. ISME J. 6, 1148-1158 (2012).
93. Pal, C., Maciá, M. D., Oliver, A., Schachar, I. & Buckling, A. Coevolution with viruses drives the evolution of bacterial mutation rates. Nature 450, 1079-1081 (2007).
94. Gómez, P. & Buckling, A. Coevolution with phages does not influence the evolution of bacterial mutation rates in soil. ISME J. 7, 2242-2244 (2013).
95. Vogwill, T., Fenton, A. & Brockhurst, M. A. Coevolving parasites enhance the diversity-decreasing effect of dispersal. Biol. Lett. 7, 578-580 (2011).
96. Friman, V.P. & Buckling, A. Effects of predation on real-time host-parasite coevolutionary dynamics. Ecol. Lett. 16, 39-46 (2013).
97. Friman, V.P. & Buckling, A. Phages can constrain protist predation-driven attenuation of Pseudomonas aeruginosa virulence in multienemy communities. ISME J. 8, 1820-1830 (2014).
98. Penner, J. C. et al. Pf4 bacteriophage produced by Pseudomonas aeruginosa inhibits Aspergillus fumigatus metabolism via iron sequestration. Microbiology 162, 1583-1594 (2016).
99. Abdallah, K., Hartman, K., Pletzer, D., Zhurina, D. & Ullrich, M. S. The bacteriophage-derived transcriptional regulator, LscR, activates the expression of levansucrase genes in Pseudomonas syringae. Mol. Microbiol. 102, 1062-1074 (2016).
100. Hosseinidoust, Z., Tufenkji, N. & van de Ven, T. G. M. Formation of biofilms under phage predation: considerations concerning a biofilm increase. Biofouling 29, 457-468 (2013).
101. Rice, S. A. et al. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J. 3, 271-282 (2009).
102. Secor, P. R. et al. Filamentous bacteriophage promote biofilm assembly and function. Cell Host Microbe 18, 549-559 (2015).
103. Hui, J. G. K., Mai-Prochnow, A., Kjelleberg, S., McDougald, D. & Rice, S. A. Environmental cues and genes involved in establishment of the superinfective Pf4 phage of Pseudomonas aeruginosa. Front. Microbiol. 5, 654 (2014).
104. Petrova, O. E., Schurr, J. R., Schurr, M. J. & Sauer, K. The novel Pseudomonas aeruginosa two-component regulator BfmR controls bacteriophage-mediated lysis and DNA release during biofilm development through PhdA. Mol. Microbiol. 81, 767-783 (2011).
105. Gloag, E. S. et al. Self-organization of bacterial biofilms is facilitated by extracellular DNA. Proc. Natl Acad. Sci. USA 110, 11541-11546 (2013).
106. Turnbull, L. et al. Explosive cell lysis as a mechanism for the biogenesis of bacterial membrane vesicles and biofilms. Nat. Commun. 7, 11220 (2016).
107. Le, S. et al. Chromosomal DNA deletion confers phage resistance to Pseudomonas aeruginosa. Sci. Rep. 4, 4738 (2014).
108. Hosseinidoust, Z., van de Ven, T. G. M. & Tufenkji, N. Evolution of Pseudomonas aeruginosa virulence as a result of phage predation. Appl. Environ. Microbiol. 79, 6110-6116 (2013).
109. Waldor, M. K. & Mekalanos, J. J. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 272, 1910-1914 (1996).
110. Nakayama, K., Kanaya, S., Ohnishi, M., Terawaki, Y. & Hayashi, T. The complete nucleotide sequence of ?CTX, a cytotoxin-converting phage of Pseudomonas aeruginosa: implications for phage evolution and horizontal gene transfer via bacteriophages. Mol. Microbiol. 31, 399-419 (1999).
111. Taylor, V. L., Udaskin, M. L., Islam, S. T. & Lam, J. S. The D3 bacteriophage ?polymerase inhibitor (Iap) peptide disrupts Oantigen biosynthesis through mimicry of the chain length regulator Wzz in Pseudomonas aeruginosa. J. Bacteriol. 195, 4735-4741 (2013).
112. Davies, E. V. et al. Temperate phages enhance pathogen fitness in chronic lung infection. ISME J. 10, 2553-2555 (2016).
113. Lemieux, A.A. et al. Genes required for free phage production are essential for Pseudomonas aeruginosa chronic lung infections. J. Infect. Dis. 213, 395-402 (2016).
114. Chan, B. K. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 (2016).
115. Zhang, Q.G. & Buckling, A. Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol. Appl. 5, 575-582 (2012).
116. Summers, W. C. Bacteriophage therapy. Annu. Rev. Microbiol. 55, 437-451 (2001).
117. Górski, A. et al. Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front. Microbiol. 7, 1515 (2016).
118. Cisek, A. A., Da?browska, I., Gregorczyk, K. P. & Wyz?ewski, Z. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr. Microbiol. 74, 277-283 (2017).
119. Loc-Carrillo, C. & Abedon, S. T. Pros and cons of phage therapy. Bacteriophage 1, 111-114 (2014).
120. Pirnay, J.P. et al. Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32, 2173-2179 (2015).
121. Danis-Wlodarczyk, K. et al. A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections. Sci. Rep. 6, 28115 (2016).
122. Cooper, C. J., Denyer, S. P. & Maillard, J.Y. Stability and purity of a bacteriophage cocktail preparation for nebulizer delivery. Lett. Appl. Microbiol. 58, 118-122 (2014).
123. Sahota, J. S. et al. Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J. Aerosol Med. Pulm. Drug Deliv. 28, 353-360 (2015).
124. Beeton, M. L., Alves, D. R., Enright, M. C. & Jenkins, A. T. A. Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model. Int. J. Antimicrob. Agents 46, 196-200 (2015).
125. Olszak, T. et al. In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients. Appl. Microbiol. Biotechnol. 99, 6021-6033 (2015).
126. Henry, M., Lavigne, R. & Debarbieux, L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob. Agents Chemother. 57, 5961-5968 (2013).
127. Furusawa, T. et al. Phage therapy is effective in a mouse model of bacterial equine keratitis. Appl. Environ. Microbiol. 82, 5332-5339 (2016).
128. McVay, C. S., Velásquez, M. & Fralick, J. A. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 51, 1934-1938 (2007).
129. Gorski, A. et al. Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 46, 313-319 (2006).
130. ?usiak-Szelachowska, M. et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 295-304 (2014).
131. Górski, A. et al. in Advances in Virus Research Vol. 83 (eds Lobocka, M. & Szybalski, W.) 41-71 (Elsevier, 2012).
132. Hodyra-Stefaniak, K. et al. Mammalian host-versus-phage immune response determines phage fate in vivo. Sci. Rep. 5, 14802 (2015).
133. Górski, A. & Weber-Dabrowska, B. The potential role of endogenous bacteriophages in controlling invading pathogens. Cell. Mol. Life Sci. 62, 511-519 (2005).
134. Budynek, P., Da?browska, K., Skaradziń ski, G. & Górski, A. Bacteriophages and cancer. Arch. Microbiol. 192, 315-320 (2010).
135. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02116010 (2015).
136. Rose, T. et al. Experimental phage therapy of burn wound infection: difficult first steps. Int. J. Burns Trauma 4, 66-73 (2014).
137. Marza, J. A., Soothill, J. S., Boydell, P. & Collyns, T. A. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32, 644-646 (2006).
138. Wright, A., Hawkins, C. H., Anggard, E. E. & Harper, D. R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349-357 (2009).
139. Markoishvili, K., Tsitlanadze, G., Katsarava, R., Morris, J. G. & Sulakvelidze, A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol. 41, 453-458 (2002).
140. Weber-Da?browska, B. et al. Bacteriophage procurement for therapeutic purposes. Front. Microbiol. 7, 1177 (2016).
141. Saussereau, E. et al. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin. Microbiol. Infect. 20, O983-O990 (2014).
142. Morello, E. et al. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS ONE 6, e16963 (2011).
143. Kutateladze, M. & Adamia, R. Phage therapy experience at the Eliava Institute. Med. Mal. Infect. 38, 426-430 (2008).
144. Kutateladze, M. & Adamia, R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 28, 591-595 (2010).
145. Hawkins, C., Harper, D., Burch, D., Änggard, E. & Soothill, J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet. Microbiol. 146, 309-313 (2010).
146. Khairnar, K. et al. Novel bacteriophage therapy for controlling metallo-beta-lactamase producing Pseudomonas aeruginosa infection in Catfish. BMC Vet. Res. 9, 264 (2013).
147. Park, S. C. & Nakai, T. Bacteriophage control of Pseudomonas plecoglossicida infection in ayu Plecoglossus altivelis. Dis. Aquat. Organ. 53, 33-39 (2003).
148. Rombouts, S. et al. Characterization of novel bacteriophages for biocontrol of bacterial blight in leek caused by Pseudomonas syringae pv. porri. Front. Microbiol. 7, 279 (2016).
149. Czaplewski, L. et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect. Dis. 16, 239-251 (2016).
150. Briers, Y. et al. Engineered endolysin-based 'artilysins' to combat multidrug-resistant Gram-negative pathogens. mBio 5, e0137914 (2014).
151. Defraine, V. et al. Efficacy of artilysin art175 against resistant and persistent Acinetobacter baumannii. Antimicrob. Agents Chemother. 60, 3480-3488 (2016).
152. Fischetti, V. A. Bacteriophage endolysins: A novel antiinfective to control Gram-positive pathogens. Int. J. Med. Microbiol. 300, 357-362 (2010).
153. Briers, Y. et al. Art175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 58, 3774-3784 (2014).
154. Pirnay, J.P. et al. The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm. Res. 28, 934-937 (2011).
155. Bikard, D. et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32, 1146-1150 (2014).
156. Citorik, R. J., Mimee, M. & Lu, T. K. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 32, 1141-1145 (2014).
157. Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J. & Lu, T. K. Genetically engineered phages: A review of advances over the last decade. Microbiol. Mol. Biol. Rev. 80, 523-543 (2016).
158. Gerstmans, H., Rodríguez-Rubio, L., Lavigne, R. & Briers, Y. From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria. Biochem. Soc. Trans. 44, 123-128 (2016).
159. Citorik, R. J., Mimee, M. & Lu, T. K. Bacteriophage-based synthetic biology for the study of infectious diseases. Curr. Opin. Microbiol. 19, 59-69 (2014).
160. Woolston, B. M., Edgar, S. & Stephanopoulos, G. Metabolic engineering: past and future. Annu. Rev. Chem. Biomol. Eng. 4, 259-288 (2013).
161. Maynard, N. D., Gutschow, M. V., Birch, E. W. & Covert, M. W. The virus as metabolic engineer. Biotechnol. J. 5, 686-694 (2010).
162. Ackermann, H.W. 5500 phages examined in the electron microscope. Arch. Virol. 152, 227-243 (2007).
163. Lavigne, R., Seto, D., Mahadevan, P., Ackermann, H.W. & Kropinski, A. M. Unifying classical and molecular taxonomic classification: Analysis of the Podoviridae using BLASTP-based tools. Res. Microbiol. 159, 406-414 (2008).
164. Lavigne, R. et al. Classification of Myoviridae bacteriophages using protein sequence similarity. BMC Microbiol. 9, 224 (2009).
165. Simmonds, P. et al. Consensus statement: virus taxonomy in the age of metagenomics. Nat. Rev. Microbiol. 15, 161-168 (2017).
166. Kramberger, P., Urbas, L. & Štrancar, A. Downstream processing and chromatography based analytical methods for production of vaccines, gene therapy vectors, and bacteriophages. Hum. Vaccin. Immunother. 11, 1010-1021 (2015).
167. Adriaenssens, E. M. et al. CIM® monolithic anion-exchange chromatography as a useful alternative to CsCl gradient purification of bacteriophage particles. Virology 434, 265-270 (2012).
168. Merabishvili, M. et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4, e4944 (2009).
169. Ryan, E. M., Gorman, S. P., Donnelly, R. F. & Gilmore, B. F. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J. Pharm. Pharmacol. 63, 1253-1264 (2011).
170. Vandenheuvel, D. et al. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur. J. Pharm. Biopharm. 84, 578-582 (2013).
171. Leung, S. S. Y. et al. Production of inhalation phage powders using spray freeze drying and spray drying techniques for treatment of respiratory infections. Pharm. Res. 33, 1486-1496 (2016).
172. Vandenheuvel, D., Meeus, J., Lavigne, R. & Van den Mooter, G. Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix. Int. J. Pharm. 472, 202-205 (2014).
173. Singla, S. et al. Phospholipid vesicles encapsulated bacteriophage: A novel approach to enhance phage biodistribution. J. Virol. Methods 236, 68-76 (2016).